Commentary on T1-Weighted Hypersignal in the Deep Cerebellar Nuclei after Repeated Administrations of Gadolinium-Based Contrast Agents in Healthy Rats: Difference between Linear and Macrocyclic Agents

Investigative Radiology

Volumn 50, Issue 8, 2015, Pages 481-482

  Runge, Val M ^a  

^a University Hospital Zurich Institut fur Diagnostische Radiologie   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

GADOBUTROL; GADODIAMIDE; GADOLINIUM; GADOLINIUM CHELATE; GADOLINIUM PENTETATE MEGLUMINE; GADOTERATE MEGLUMINE; GADOTERIDOL; GADOVERSETAMIDE; METAL CHELATE; CONTRAST MEDIUM; GADOLINIUM PENTETATE; MEGLUMINE; ORGANOMETALLIC COMPOUND;

ACUTE KIDNEY FAILURE; CEREBELLUM NUCLEUS; CHRONIC KIDNEY DISEASE; CLINICAL ASSESSMENT; DENTATE NUCLEUS; DRUG BRAIN LEVEL; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FUNCTION; MASS SPECTROMETRY; NEPHROGENIC SYSTEMIC FIBROSIS; NONHUMAN; NOTE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRACTICE GUIDELINE; PRIORITY JOURNAL; RAT; URINARY EXCRETION; ANIMAL; FEMALE; METABOLISM;

ANIMALS; CEREBELLAR NUCLEI; CONTRAST MEDIA; FEMALE; GADOLINIUM DTPA; MAGNETIC RESONANCE IMAGING; MEGLUMINE; ORGANOMETALLIC COMPOUNDS;

EID: 84937575803     PISSN: 00209996     EISSN: 15360210     Source Type: Journal    
DOI: 10.1097/RLI.0000000000000182     Document Type: Note

References (22)

1. Robert P, Lehéricy S, Sylvie G, T1-weighted hypersignal in the deep cerebellar nuclei following repeated administrations of gadolinium-based contrast agents in healthy rats: difference between linear and macrocyclic agents. Invest Radiol. 2015; 50: 473-480.
2. Errante Y, Cirimele V, Mallio CA, Progressive increase of T1 signal intensity of the dentate nucleus on unenhanced magnetic resonance images is associated with cumulative doses of intravenously administered gadodiamide in patients with normal renal function, suggesting dechelation. Invest Radiol. 2014; 49: 685-690.
3. Kanda T, Ishii K, Kawaguchi H, High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material. Radiology. 2014; 270: 834-841.
4. Kanda T, Osawa M, Oba H, High signal intensity in dentate nucleus on unenhanced T1-weighted MR images: association with linear versus macrocyclic gadolinium chelate administration. Radiology. 2015; 275: 803-809.
5. Quattrocchi CC, Mallio CA, Errante Y, Gadodiamide and dentate nucleus T1 hyperintensity in patients with meningioma evaluated by multiple follow-up contrast-enhanced magnetic resonance examinations with no systemic interval therapy. Invest Radiol. 2015; 50: 470-472.
6. Radbruch A, Weberling LD, Kieslich PJ, Gadolinium retention in the dentate nucleus and globus pallidus is dependent on the class of contrast agent. Radiology. 2015; 275: 783-791.
7. McDonald RJ, McDonald JS, Kallmes DF, Intracranial gadolinium deposition after contrast-enhanced MR imaging. Radiology. 2015; 275: 772-782.
8. Kanda T, Fukusato T, Matsuda M, Gadolinium-based contrast agent accumulates in the brain even in subjects without severe renal dysfunction: evaluation of autopsy brain specimens with inductively coupled plasma mass spectroscopy. Radiology. 2015; 142690.
9. Grobner T,. Gadolinium-a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant. 2006; 21: 1104-1108.
10. Khurana A, Runge VM, Narayanan M, Nephrogenic systemic fibrosis: a review of 6 cases temporally related to gadodiamide injection (Omniscan). Invest Radiol. 2007; 42: 139-145.
11. Rydahl C, Thomsen HS, Marckmann P,. High prevalence of nephrogenic systemic fibrosis in chronic renal failure patients exposed to gadodiamide, a gadolinium-containing magnetic resonance contrast agent. Invest Radiol. 2008; 43: 141-144.
12. Sieber MA, Pietsch H, Walter J, A preclinical study to investigate the development of nephrogenic systemic fibrosis: a possible role for gadolinium-based contrast media. Invest Radiol. 2008; 43: 65-75.
13. Pietsch H, Lengsfeld P, Steger-Hartmann T, Impact of renal impairment on long-term retention of gadolinium in the rodent skin following the administration of gadolinium-based contrast agents. Invest Radiol. 2009; 44: 226-233.
14. Sieber MA, Steger-Hartmann T, Lengsfeld P, Gadolinium-based contrast agents and NSF: evidence from animal experience. J Magn Reson Imaging. 2009; 30: 1268-1276.
15. de Haen C,. Conception of the first magnetic resonance imaging contrast agents: a brief history. Top Magn Reson Imaging. 2001; 12: 221-230.
16. Runge VM, Stewart RG, Clanton JA, Paramagnetic NMR contrast agents: potential oral and intravenous agents. Presented at the annual meeting of the Radiological Society of North America, November 28-December 9, 1982.
17. Runge VM, Clanton JA, Lukehart CM, Paramagnetic agents for contrast-enhanced NMR imaging: a review. AJR Am J Roentgenol. 1983; 141: 1209-1215.
18. Runge VM, Clanton JA, Price AC, Dyke award. Evaluation of contrast-enhanced MR imaging in a brain-abscess model. AJNR Am J Neuroradiol. 1985; 6: 139-147.
19. Runge VM, Bradley WG, Brant-Zawadzki MN, Clinical safety and efficacy of gadoteridol: a study in 411 patients with suspected intracranial and spinal disease. Radiology. 1991; 181: 701-709.
20. Runge VM,. Safety of approved MR contrast media for intravenous injection. J Magn Reson Imaging. 2000; 12: 205-213.
21. Runge VM, Ai T, Hao D, The developmental history of the gadolinium chelates as intravenous contrast media for magnetic resonance. Invest Radiol. 2011; 46: 807-816.
22. Nunn AD,. The cost of developing imaging agents for routine clinical use. Invest Radiol. 2006; 41: 206-212.